35418-08-7

Basic information

• Product Name: 3-(3-Amino-phenyl)-propionic acid methyl ester
• Synonyms: 3-(3-Amino-phenyl)-propionic acid methyl ester;methyl 3-(3-aminophenyl)propanoate
• CAS NO: 35418-08-7
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.2157
• Product Categories: Pharmaceutical intermediate
• Mol File: 35418-08-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 298.8 °C at 760 mmHg
• Flash Point: 154.6 °C
• Appearance: /
• Density: 1.112 g/cm³
• CAS DataBase Reference: 3-(3-Amino-phenyl)-propionic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-Amino-phenyl)-propionic acid methyl ester(35418-08-7)
• EPA Substance Registry System: 3-(3-Amino-phenyl)-propionic acid methyl ester(35418-08-7)

Safety Data

• Hazardous Substances Data: 35418-08-7(Hazardous Substances Data)

Usage

General Description

3-(3-Amino-phenyl)-propionic acid methyl ester, also known as Mepivacaine, is a local anesthetic medication that works by blocking nerve signals in the body. It is often used during medical and dental procedures to numb a specific area of the body, offering temporary relief from pain. Mepivacaine works by inhibiting the influx of sodium ions through voltage-gated sodium channels in the neuronal cell membrane, which prevents the generation of action potentials and therefore stops the transmission of pain signals to the brain. This chemical is commonly found in the form of an injection or a topical cream and is generally considered safe and effective when used as directed by a healthcare professional.

Upstream product

• 659-04-1 methyl 3-nitrocinnamate 
• 7440-44-0 pyrographite 
• 58186-45-1 3-(3-amino-phenyl)-acrylic acid methyl ester 
• 99-61-6 3-nitro-benzaldehyde 
• 555-68-0 (E)-3-Nitrocinnamic acid 
• 67-56-1 methanol 
• 1664-54-6 3-(3-aminophenyl)propionic acid 
• 22768-05-4 methyl 3-(3-nitrophenyl)propanoate 

Downstream Products

• 141887-74-3 methyl 3-(3-(tritylamino)phenyl)propionate 
• 162471-97-8 methyl 3-(3-phenylazophenyl)propanoate 
• 162472-04-0 3-(3-phenylazophenyl)propanol 
• 1026541-26-3 3-[3-(N'-Phenyl-hydrazino)-phenyl]-propan-1-ol 
• 141887-76-5 4-(3-azidophenyl)-1-(dimethoxyphosphoryl)-2-butanone 
• 141887-79-8 17-(3-azidophenyl)-15-dehydro-18,19,20-trinorisocarbacyclin methyl ester 
• 141887-75-4 1-(dimethoxyphosphoryl)-4-(3-(tritylamino)phenyl)-2-butanone 
• 943345-21-9 3-(3-{[5-(4-Methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}phenyl)propanoic acid methyl ester 

Relevant articles and documents

4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads

Multitarget drugs are an emerging alternative to combination therapies. In three iterative cycles of design, synthesis, and biological evaluation, we developed a novel type of potent hybrid inhibitors of bromodomain, and extra-terminal (BET) proteins and histone deacetylases (HDACs) based on the BET inhibitor XD14 and well-established HDAC inhibitors. The most promising new hybrids, 49 and 61, displayed submicromolar inhibitory activity against HDAC1-3 and 6, and BRD4(1), and possess potent antileukemia activity. 49 induced apoptosis more effectively than the combination of ricolinostat and birabresib (1:1). The most balanced dual inhibitor, 61, induced significantly more apoptosis than the related control compounds 62 (no BRD4(1) affinity) and 63 (no HDAC inhibition) as well as the 1:1 combination of both. Additionally, 61 was well tolerated in an in vivo zebrafish toxicity model. Overall, our data suggest an advantage of dual HDAC/BET inhibitors over the combination of two single targeted compounds.

FUNCTIONALIZED NANOLUC INHIBITORS

Compounds that may inhibit Oplophorus-derived luciferases are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.

MODULATION OF PROTEIN FUNCTIONALITIES

New methods for the rational identification of molecules capable of interacting with specific naturally occurring proteins are provided, in order to yield new pharmacologically important compounds and treatment modalities. Broadly, the method comprises the steps of identifying a switch control ligand forming a part of a particular protein of interest, and also identifying a complemental switch control pocket forming a part of the protein and which interacts with said switch control ligand. The ligand interacts in vivo with the pocket to regulate the conformation and biological activity of the protein such that the protein assumes a first conformation and a first biological activity upon the ligand-pocket interaction, and assumes a second, different conformation and biological activity in the absence of the ligand-pocket interaction. Next, respective samples of said protein in the first and second conformations are provided, and these are screened against one or more candidate molecules by contacting the molecules and the samples. Thereupon, small molecules which bind with the protein at the region of the pocket may be identified. Novel protein-modulator adducts and methods of altering protein activity are also provided.